固体癌治疗市场规模、份额和成长分析（按治疗方法、癌症适应症、最终用户和地区划分）—2026年至2033年产业预测

预计到 2024 年，全球固体癌治疗市场规模将达到 1,915.8 亿美元，到 2025 年将达到 2,072.9 亿美元，到 2033 年将达到 3,894 亿美元，预测期（2026-2033 年）的复合年增长率为 8.2%。

由于人口老化和生活方式改变导致风险因素增加，包括乳癌、肺癌、大肠癌和摄护腺癌在内的多种癌症发生率不断上升，全球固体癌治疗市场正经历强劲成长。对有效治疗方案日益增长的需求促使人们采用标靶治疗和免疫疗法等先进治疗方法，这些疗法与传统化疗相比，已显示出更佳的患者疗效。新型治疗方法的监管核准数量激增以及强大的抗癌药物研发管线进一步推动了这一增长。此外，製药公司对基于生物标记和基因组分析的个人化医疗研发投入、医疗费用支出不断增长以及有利的医保报销政策也是推动市场扩张的主要因素。

全球固体癌治疗市场按治疗方法类型、癌症适应症、最终用户和地区进行细分。依治疗方法类型划分，可分为化疗、标靶治疗、免疫疗法、荷尔蒙疗法和其他疗法。依癌症适应症划分，可分为乳癌、肺癌、大肠癌、摄护腺癌、肝癌和其他癌症。依最终用户划分，可分为医院、癌症研究中心和专科诊所。依地区划分，可分为北美、欧洲、亚太、拉丁美洲以及中东和非洲。

推动全球固体癌药物市场发展的因素

网路攻击（包括勒索软体、网路钓鱼和资料外洩）的发生率和复杂性不断增加，加剧了企业面临的安全漏洞。这种不断扩大的威胁环境迫使企业加大对防护措施的投入，从而推动了全球固体癌治疗市场的成长。各行各业的公司都在积极寻求有效的解决方案来降低风险并确保业务顺利运营，这刺激了对创新治疗方法的需求。随着企业将防御这些威胁列为优先事项，固体癌治疗市场展现出强劲的成长势头，反映出在应对不断变化的挑战时，人们对健康和安全的重视程度日益提高。

限制全球固态肿瘤药物市场的因素

全球固态肿瘤治疗市场面临许多挑战，其中，先进疗法（尤其是生物製药和免疫疗法）的高昂费用限制了中低收入地区患者的治疗机会。有限的保险覆盖范围和高额的自付费用进一步阻碍了这些治疗方法的应用，尤其是在资源匮乏的地区。这些经济障碍造成了治疗机会的不平等，阻碍了创新治疗方法的公平获取，并最终限制了全球固体癌治疗市场的整体成长和渗透。消除这些障碍对于提高全球癌症治疗的可近性和公平性至关重要。

全球固体癌抗癌药物市场趋势

全球固体癌治疗市场正呈现出人工智慧与数位病理学融合的显着趋势，这大大促进了治疗的个人化。这些先进技术简化了肿瘤特征分析，使肿瘤科医师能够制定个人化的治疗策略，进而改善患者的治疗效果。借助人工智慧的分析能力，医疗机构可以提高治疗反应预测的准确性，同时加速精准医疗在各种癌症类型中的应用。这种转变不仅优化了个别患者照护，也推动了治疗领域的创新，为投资这些前沿解决方案的相关人员带来了竞争优势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

全球固体癌治疗药物市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 化疗
• 标靶治疗
• 免疫疗法
• 荷尔蒙疗法
• 其他的

全球固体癌药物市场规模（按癌症适应症和复合年增长率划分）（2026-2033 年）

• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 肝癌
• 其他的

全球固体癌治疗药物市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 癌症研究中心
• 专科诊所

全球固体癌治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• AstraZeneca plc（United Kingdom）
• Bristol Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Sanofi SA（France）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Gritstone Bio, Inc.（USA）
• Black Diamond Therapeutics, Inc.（USA）

结论与建议

Global Solid Tumor Therapeutics Market size was valued at USD 191.58 Billion in 2024 and is poised to grow from USD 207.29 Billion in 2025 to USD 389.4 Billion by 2033, growing at a CAGR of 8.2% in the forecast period (2026-2033).

The global solid tumor therapeutics market is experiencing robust growth due to rising incidences of various cancers, such as breast, lung, colorectal, and prostate cancers, fueled by an aging population and lifestyle changes that elevate risk factors. The demand for effective therapeutic solutions is increasing, leading to the adoption of advanced treatments like targeted therapies and immunotherapies, which are demonstrating improved patient outcomes compared to traditional chemotherapy. This growth is further supported by a surge in regulatory approvals for novel treatments and a strong pipeline of oncology drugs. Pharmaceutical investments in research and development for personalized medicine, enhanced by biomarkers and genomic profiling, alongside higher healthcare expenditures and favorable reimbursement rates, are key factors boosting market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Solid Tumor Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Solid Tumor Therapeutics Market Segments Analysis

The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Solid Tumor Therapeutics Market

The rising incidence and complexity of cyberattacks, such as ransomware, phishing, and data breaches, have heightened the vulnerabilities faced by organizations. This growing threat environment prompts businesses to expand their investments in protective measures, thereby driving the growth of the global solid tumor therapeutics market. Companies across various sectors are increasingly seeking effective solutions to mitigate risks and ensure seamless operations, fueling demand for innovative therapies. As organizations prioritize safeguarding against these threats, the market for solid tumor therapeutics is witnessing significant momentum, reflecting a broader commitment to health and security in the face of evolving challenges.

Restraints in the Global Solid Tumor Therapeutics Market

The Global Solid Tumor Therapeutics market faces significant challenges due to the high costs associated with advanced treatments, particularly biologics and immunotherapies, which restrict access for patients in lower- and middle-income areas. Limited insurance coverage and substantial out-of-pocket expenses further hinder the adoption of these therapies, especially in resource-constrained environments. These financial obstacles create disparities in treatment availability, preventing a fair distribution of innovative therapies and ultimately limiting the overall growth and penetration of the global solid tumor therapeutics market. Addressing these barriers is crucial for enhancing accessibility and equality in cancer treatment worldwide.

Market Trends of the Global Solid Tumor Therapeutics Market

The Global Solid Tumor Therapeutics market is witnessing a notable trend towards the integration of AI and digital pathology, significantly enhancing treatment personalization. These advanced technologies streamline tumor characterization, enabling oncologists to develop tailored therapeutic strategies that improve patient outcomes. By leveraging AI's analytical capabilities, healthcare providers can enhance the predictability of treatment responses while expediting the adoption of precision medicine across various cancer types. This shift not only optimizes individual patient care but also drives innovation within the therapeutic landscape, establishing a competitive edge for stakeholders who invest in these cutting-edge solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Solid Tumor Therapeutics Market Size by Therapy Types & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Solid Tumor Therapeutics Market Size by Cancer Indication & CAGR (2026-2033)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

Global Solid Tumor Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Research Centers
• Specialty Clinics

Global Solid Tumor Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Types, Cancer Indication, End User)
  • US
  • Canada
• Europe (Therapy Types, Cancer Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Types, Cancer Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Types, Cancer Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Types, Cancer Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Black Diamond Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations